News

Amoun is a major company in Egypt’s pharmaceutical sector and owns brands in therapeutic areas such as anti-hypertensives, broad-spectrum antibiotics and anti-diarrheals. Currently, Amoun expects to reach EGP1.75bn

C2N-8E12 is a humanized antibody that targets the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer’s disease (AD).

AstraZeneca has completed the divestment of non-US global rights of its gastroenterology drug Entocort to Tillotts Pharma (Tillotts), part of the Zeria Group, for $215m. Entocort (budesonide) is

The first product to offer two convenient solutions, the Estroven Intimacy Kit includes a dietary supplement to support a healthy libido* and a vaginal moisturizer designed to foster

NantHealth’s existing cOS, eviti and omics platforms, combined with Harris’ FusionFX® suite of products, delivers on the promise of whole health systems integration and revolutionizes the patient-clinician experience

The FDA granted orphan drug status for Anisina under the US Orphan Drug Act following a review by the agency of a package of pre-clinical data from preclinical

The company said that its bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. Additionally, Hospira intends to launch a

The agreement expands upon the strategic manufacturing alliance entered in December 2012 concerning the North Carolina facility. As part of the new deal, Eisai will transfer to Biogen

Epiduo Forte Gel is the first combination of retinoid, adapalene and benzoyl peroxide, developed for the moderate to severe acne population. Acne is the most common skin condition